Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Urate-Lowering Therapy in the Treatment of Patients with Chronic Kidney Disease

Summarized from The New England Journal of Medicine  |  

In a new-patient consultation for joint pain, you see a 75-year-old man with a history of dementia, stage 3a chronic kidney disease (CKD) and nephrolithiasis. He has a uric acid level of 7.5 mg/dL. His medication list includes 300 mg daily allopurinol. What is NOT an indication for allopurinol? CKD-FIX Elevated serum urate levels are…

Key Research in Axial Spondyloarthritis Encapsulated

David S. Pisetsky, MD, PhD  |  

Our understanding of (axSpA) has really changed, especially with regard to male-female differences. In this report, we identify important research on axSpA presented at ACR Convergence 2024, summarize the abstracts and comment on why each is important, addressing the relevance for clinicians and the potential impact on future research.

Are Sacroiliac Joint MRIs Accurate in Routine Clinical Practice?

Anna E.F. Hadsbjerg, Simon Krabbe, Nora Vladimirova, Adrian Ciurea, Kristyna Bubova, Monika Gregová, Michael Nissen, Burkhard Moeller, Raphael Micheroli, Susanne Pedersen, Jakub Zavada, Ziga Snoj, Karlo Pintaric, Bjorn Gudbjornsson, Ziga Rotar, Iris Eshed, Iwona Sudol-Szopinska, Kasper Gosvig, Torsten Diekhoff, Robert Lambert, Manouk de hOoge, Helena V.G. Elmo, Merete Hetland, Lykke Oernbjerg & Mikkel Ostergaard  |  

Hadsbjerg et al. compared assessments of sacroiliac joint MRIs in local MRI reports from routine care in five European countries with re-reads by central experts in patients with a diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) to estimate the extent of over- or under-reporting of features and misclassification.

Top Research in Psoriatic Arthritis Presented at ACR Convergence 2024

David S. Pisetsky, MD, PhD  |  

Editor’s note: What research on psoriatic arthritis (PsA) presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. Dr. Pisetsky, a professor of medicine and immunology…